Mecillinam/clavulanate combination: A possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2424-2428

  Lampri, Niki ^a   Galani, Irene ^a   Poulakou, Garyphallia ^a   Katsarolis, Ioannis ^a   Petrikkos, George ^a   Giamarellou, Helen ^b   Souli, Maria ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HYGEIA HOSPITAL   (Greece)

Author keywords

Combinations; Community; Enterobacteriaceae; Multidrug resistance; Synergy

Indexed keywords

BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE TEM 1; CLAVULANIC ACID; MECILLINAM;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COLONY FORMING UNIT; DRUG POTENTIATION; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GREECE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; OUTPATIENT; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; URINARY TRACT INFECTION;

AMDINOCILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CLAVULANIC ACID; COMMUNITY-ACQUIRED INFECTIONS; DNA, BACTERIAL; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GREECE; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; URINARY TRACT INFECTIONS;

EID: 84866601287     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks215     Document Type: Article

References (14)

1. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO. SENS study revisited. Int J Antimicrob Agents 2012; 39: 45-51.
2. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
3. Katsarolis I, Poulakou G, Athanasia S et al. Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. Int J Antimicrob Agents 2010; 35: 62-7.
4. Souli M, Rekatsina PD, Chryssouli Z et al. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 2009; 53: 2133-5.
5. Brenwald NP, Andrews J, Fraise AP. Activity of mecillinam against AmpC β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2006; 58: 223-4.
6. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii=19044.
7. Wooton M, Walsh TR, Macfarlane L et al. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2010; 65: 79-81.
8. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrumb-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010; 54: 4006-8.
9. Titelman E, Iversen A, Kahlmeter G et al. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011; 119: 853-63.
10. Tärnberg M, Ostholm-Balkhed A, Monstein HJ et al. In vitro activity of b-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011; 30: 981-7.
11. Neu HC. Synergistic activity of mecillinam in combination with the b-lactamase inhibitors clavulanic acid and sulbactam. Antimicrob Agents Chemother 1982; 22: 518-9.
12. Thomas K, Weinbren MJ, Warner M et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006; 57: 367-8.
13. Nicolle LE, Mulvey MR. Successful treatment of CTX-M ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 2007; 39: 748-9.
14. Titelman E, Iversen A, Kalin M et al. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extendedspectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012; 18: 189-92.